A compound according to formula I wherein: R 1 is heterocyclyl or heteroaryl selected from the group consisting of pyrazolyl, triazolyl oxadiazolyl, oxazolyl, imidazolyl, isoxazolyl, pyrrolidinyl, piperidinyl or morpholinyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 hydroxyalkyl, halogen, hydroxyl and oxo; Ar is phenyl or pyridinyl optionally substituted by 1 to 5 groups independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 cycloalkyl, halogen, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 acylamino, cyano and nitro; R 2 is selected from the group consisting of (a) C 1-10 alkyl, (b) C 1-6 haloalkyl, (c) heterocyclyl or heterocyclyl-C 1-6 alkyl wherein said heterocycle or heterocyclyl-C 1-6 alkyl is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl,2-oxabicyclo[2.2.1]heptan-5-yl, oxetanyl, piperidinyl, N-C 1-6 alkyl-piperidinyl, 1,1-dioxothietan-3-yl, thietan-3-yl, and N-C 1-6 alkyl-2-oxo-pyrrolidinyl and wherein said heterocyclyl or heterocyclyl-C 1-6 alkyl is optionally substituted by 1 to 3 groups independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 acyloxy-C 1-2 alkyl, halogen, hydroxyl, phenyl, C 1-3 hydroxyalkyl and oxo, (d) C 3-7 cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkyl wherein said cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkyl are optionally substituted by one to three hydroxyl, C 1-3 alkoxy or halo groups, (e) C 1-6 heteroalkyl wherein the heteroalkyl moiety at least includes C 1-6 hydroxyalkyl or C 1-3 alkoxy-C 1-6 alkoxy, (f) heteroaryl wherein said heteroaryl is selected from the group consisting of pyrazolyl and pyridinyl wherein said heteroaryl is optionally independently substituted with one to three groups selected from the group consisting of C 1-6 alkyl groups, C 1-6 haloalkyl and halogen. and (g) C 1-3 cyanoalkyl; R 3 is hydrogen or halogen; or, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. R 1 is heterocyclyl or heteroaryl selected from the group consisting of pyrazolyl, triazolyl oxadiazolyl, oxazolyl, imidazolyl, isoxazolyl, pyrrolidinyl, piperidinyl or morpholinyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 hydroxyalkyl, halogen, hydroxyl and oxo; Ar is phenyl or pyridinyl optionally substituted by 1 to 5 groups independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 cycloalkyl, halogen, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 acylamino, cyano and nitro; R 2 is selected from the group consisting of (a) C 1-10 alkyl, (b) C 1-6 haloalkyl, (c) heterocyclyl or heterocyclyl-C 1-6 alkyl wherein said heterocycle or heterocyclyl-C 1-6 alkyl is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl,2-oxabicyclo[2.2.1]heptan-5-yl, oxetanyl, piperidinyl, N-C 1-6 alkyl-piperidinyl, 1,1-dioxothietan-3-yl, thietan-3-yl, and N-C 1-6 alkyl-2-oxo-pyrrolidinyl and wherein said heterocyclyl or heterocyclyl-C 1-6 alkyl is optionally substituted by 1 to 3 groups independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 acyloxy-C 1-2 alkyl, halogen, hydroxyl, phenyl, C 1-3 hydroxyalkyl and oxo, (d) C 3-7 cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkyl wherein said cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkyl are optionally substituted by one to three hydroxyl, C 1-3 alkoxy or halo groups, (e) C 1-6 heteroalkyl wherein the heteroalkyl moiety at least includes C 1-6 hydroxyalkyl or C 1-3 alkoxy-C 1-6 alkoxy, (f) heteroaryl wherein said heteroaryl is selected from the group consisting of pyrazolyl and pyridinyl wherein said heteroaryl is optionally independently substituted with one to three groups selected from the group consisting of C 1-6 alkyl groups, C 1-6 haloalkyl and halogen. and (g) C 1-3 cyanoalkyl; R 3 is hydrogen or halogen; or, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.